Prodigiosin hydrochloride
Based on 3 publication(s) in Google Scholar
Prodigiosin (Prodigiosine) hydrochloride is a red pigment produced by bacteria as a bioactive secondary metabolite. Prodigiosin hydrochloride is a potent proapoptotic agent, and inhibits Wnt/β-catenin pathway. Prodigiosin hydrochloride has antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive, and anticancer properties.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.05%
- CAS. Nr.: 56144-17-3
- Formel: C20H26ClN3O
- Molecular Weight:359.89
-
Speicherung:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-N0889
GinkgetinAutophagy Inducer -
HY-101085
SKL2001Wnt/β-catenin Pathway Agonist -
HY-10593
IQ 1Wnt/β-catenin/CBP Signaling Sustainer -
HY-120697
MSABWnt/β-Catenin Inhibitor -
HY-12238
IWR-1Wnt Signaling Inhibitor -
HY-112799
DK419Wnt/β-catenin Inhibitor -
HY-17439
Salinomycin sodium saltWnt/β-catenin Inhibitor -
HY-N0889R
Ginkgetin (Standard)Autophagy Inducer -
HY-19987
BML-284Wnt Signaling Activator -
HY-12879
IWP-4Wnt/CK1δ/ε Inhibitor -
HY-112045
Foscenvivint -
HY-A0293
Pyrvinium pamoateWnt Inhibitor
Publications Citing Use of MedChemExpress (MCE) Prodigiosin hydrochloride
More
Customer Validation & Images
-
Histological Imaging/Staining
-
WB
-
RT-PCR
-
ELISA
-
IF
Alle Parasite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
|
Plasmodium |
In Vitro
Prodigiosin (25-500 nM; 24 hours) treatment reduces the viability of breast cancer cells, with IC50 values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells[1].
Prodigiosin (25-500 nM; 24 hours) treatment significantly reduces the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin. Prodigiosin noticeably inhibits the phosphorylation of GSK3β at Ser9 in HEK293T cells, which is indicative of an increase in GSK3β activity[1].
Prodigiosin can inhibit proliferation and induce apoptosis in breast cancer cells[1].
Prodigiosin (25-500 nM; 24 hours) treatment dose-dependently blocks Wnt signaling activated by Wnt1, Wnt3, Wnt1/LRP6, Wnt3/LRP6, and Dishevelled 2 (DVL2) in transfected HEK293T cells. Prodigiosin treatment inhibits Wnt3A-CM-induced transcription in a dose-dependent manner. Prodigiosin inhibits transcription of the SuperTopFlash reporter activated by either Wnt transfection or Wnt3A treatment[1].
When applied to cultures of chytrid fungi Batrachochytrium dendrobatidis and B. salamandrivorans, Prodigiosin causes significant growth inhibition, with MIC values of 10 μM and 50 μM, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 and MDA-MB-468 cells
-
Concentration:10 nM, 25 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1000 nM, 2500 nM, 5000 nM
-
Incubation Time:24 hours, 48 hours
-
Result:Reduced the viability of breast cancer cells, with IC50 values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells.
-
Cell Line:HEK293T cells
-
Concentration:50 nM, 100 nM, 250 nM, 500 nM
-
Incubation Time:24 hours
-
Result:Significantly reduced the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice injected with MDA-MB-231 cells[1]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; twice weekly; for 3 weeks
-
Result:Significantly inhibited tumor growth in mice.
Chemical Information
-
CAS. Nr. 56144-17-3
-
Appearance Solid
-
Molecular Weight 359.89
-
Formel C20H26ClN3O
-
Color Purple to purplish red
-
SMILES
CCCCCC1=C/C(N=C1C)=C\C2=C(OC)C=C(C3=CC=CN3)N2.[H]Cl
-
Synonyms
Prodigiosine hydrochloride
-
Structure Classification
-
Initial Source
Serratia marcescens
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
Design and in vitro anticancer assessment of a click chemistry-derived dinuclear copper artificial metallo-nuclease. [Abstract]2025 Jan 7;53(1):gkae1250. PMID: 39777469 -
J Physiol Pharmacol
Prodigiosin improves acute lung injury in a rat model of rheumatoid arthritis via down-regulating the nuclear factor kappaB/nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 signaling pathway. [Abstract]2023 Feb;74(1). PMID: 37245232
Prodigiosin hydrochloride purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
HE staining disclosed the typical histological images of the lung treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin hydrochloride purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
Western blot was performed to check the protein profiles of lung damage active markers SPA and SPD treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin hydrochloride purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
RT-qPCR was implemented to ascertain the RNA and secretion levels of inflammatory cytokines TNF-a, IL-6, IL-1b, and MCP-1 treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin hydrochloride purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
ELISA was implemented to ascertain the RNA and secretion levels of inflammatory cytokines TNF-a, IL-6, IL-1b, and MCP-1 treated with Prodigiosin (PRO) (1, 3, 5 μg/mL).
Prodigiosin hydrochloride purchased from MedChemExpress. Usage Cited in: J Physiol Pharmacol. 2023 Feb;74(1). [Abstract]
TUNEL was performed to examine the apoptosis of epithelial tissues in acute lung injury of the RA rat model treated with Prodigiosin (PRO) (1, 5 μg/mL).
-
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 10 mg/mL (27.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.25 mg/mL (0.69 mM); Clear solution
This protocol yields a clear solution of ≥ 0.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.25 mg/mL (0.69 mM); Clear solution
This protocol yields a clear solution of ≥ 0.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Wang Z, et al. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13150-13155. [Content Brief]
[2]. Woodhams DC, et al. Prodigiosin, Violacein, and Volatile Organic Compounds Produced by Widespread Cutaneous Bacteria of Amphibians Can Inhibit Two Batrachochytrium Fungal Pathogens. Microb Ecol. 2018 May;75(4):1049-1062. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7786 mL | 13.8931 mL | 27.7863 mL | 69.4657 mL |
| 5 mM | 0.5557 mL | 2.7786 mL | 5.5573 mL | 13.8931 mL | |
| 10 mM | 0.2779 mL | 1.3893 mL | 2.7786 mL | 6.9466 mL | |
| 15 mM | 0.1852 mL | 0.9262 mL | 1.8524 mL | 4.6310 mL | |
| 20 mM | 0.1389 mL | 0.6947 mL | 1.3893 mL | 3.4733 mL | |
| 25 mM | 0.1111 mL | 0.5557 mL | 1.1115 mL | 2.7786 mL |
Prodigiosin hydrochloride Related Classifications
HY-100711A Related Classifications
Powered by Bioz